Actinium: CD45 monoclonal antibody Iomab-B III study achieves primary endpoint
ADC评论
November 2, 2022
On October 31, Actinium Pharmaceuticals announced that the pivotal Phase III SIERRA study of its CD45 monoclonal antibody Iomab-B (apamistamab) in patients with relapsed or
